Amicus Therapeutics, Inc. Earnings

Amicus Therapeutics, Inc.’s revenue jumped 23.72% since last year same period to $185.21Mn in the Q4 2025. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated 9.55% jump in its revenue since last 3-months.

Amicus Therapeutics, Inc.’s net profit fell -88.53% since last year same period to $1.69Mn in the Q4 2025. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated -90.23% fall in its net profits since last 3-months.

Amicus Therapeutics, Inc.’s net profit margin fell -90.73% since last year same period to 0.91% in the Q4 2025. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated -91.09% fall in its net profit margins since last 3-months.

Amicus Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.03 - a -56.92% fall from last quarter’s estimates.

Amicus Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at 0.03.

Amicus Therapeutics, Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2026. This indicates that the Amicus Therapeutics, Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.